Ionis Pharmaceuticals, Inc. Repayments of Secured Debt
Ionis Pharmaceuticals, Inc. (IONS) reported Repayments of Secured Debt of $85.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. repayments of secured debt for the quarter ending 2026-06-30 was $41.00K, a 2.50% increase year-over-year.
- Ionis Pharmaceuticals, Inc. repayments of secured debt for the quarter ending 2026-03-31 was $44.00K, a 4.76% increase year-over-year.
- Ionis Pharmaceuticals, Inc. repayments of secured debt for the quarter ending 2025-12-31 was $52.00K, a 26.83% increase year-over-year.
- Ionis Pharmaceuticals, Inc. repayments of secured debt for the quarter ending 2025-09-30 was $41.00K, a 14.58% decline year-over-year.
- Ionis Pharmaceuticals, Inc. repayments of secured debt for fiscal 2025 was $175.00K, a 4.79% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. repayments of secured debt for fiscal 2024 was $167.00K, a 4.37% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. repayments of secured debt for fiscal 2023 was $160.00K, a 99.68% decline from fiscal 2022.
- Ionis Pharmaceuticals, Inc. repayments of secured debt for fiscal 2022 was $50.69M.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $85.00K 10-Q · filed 2026-07-29 | $137.00K derived: sum of 3 quarters · filed 2026-07-29 | $178.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $44.00K 10-Q · filed 2026-04-29 | $96.00K derived: sum of 2 quarters · filed 2026-04-29 | $137.00K derived: sum of 3 quarters · filed 2026-04-29 | $177.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $93.00K derived: sum of 2 quarters · filed 2026-02-26 | $133.00K derived: sum of 3 quarters · filed 2026-07-29 | $175.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $81.00K derived: sum of 2 quarters · filed 2026-07-29 | $123.00K 10-Q · filed 2025-10-29 | $164.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $82.00K 10-Q · filed 2026-07-29 | $123.00K derived: sum of 3 quarters · filed 2026-07-29 | $171.00K derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $42.00K 10-Q · filed 2026-04-29 | $83.00K derived: sum of 2 quarters · filed 2026-04-29 | $131.00K derived: sum of 3 quarters · filed 2026-04-29 | $170.00K derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $89.00K derived: sum of 2 quarters · filed 2026-02-26 | $128.00K derived: sum of 3 quarters · filed 2026-02-26 | $167.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $87.00K derived: sum of 2 quarters · filed 2025-10-29 | $126.00K 10-Q · filed 2025-10-29 | $164.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $78.00K 10-Q · filed 2025-07-30 | $116.00K derived: sum of 3 quarters · filed 2026-02-26 | $163.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $39.00K 10-Q · filed 2025-04-30 | $77.00K derived: sum of 2 quarters · filed 2026-02-26 | $124.00K derived: sum of 3 quarters · filed 2026-02-26 | $160.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $85.00K derived: sum of 2 quarters · filed 2026-02-26 | $121.00K derived: sum of 3 quarters · filed 2026-02-26 | $160.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $83.00K derived: sum of 2 quarters · filed 2024-11-06 | $122.00K 10-Q · filed 2024-11-06 | $50.72M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $75.00K 10-Q · filed 2024-08-01 | $50.67M derived: sum of 3 quarters · filed 2025-02-19 | $50.76M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $39.00K 10-Q · filed 2024-05-07 | $50.64M derived: sum of 2 quarters · filed 2025-02-19 | $50.73M derived: sum of 3 quarters · filed 2025-02-19 | $50.73M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $50.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $50.69M derived: sum of 2 quarters · filed 2025-02-19 | $50.69M derived: sum of 3 quarters · filed 2025-02-19 | $50.69M 10-K · filed 2025-02-19 |
| 2022-09-30 | $89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $89.00K derived: sum of 2 quarters · filed 2023-11-02 | $89.00K 10-Q · filed 2023-11-02 | $89.00K derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $0.00 derived: sum of 3 quarters · filed 2024-02-21 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 10-K · filed 2024-02-21 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |